Hi,

It seems the FDA's navigating a new course with CBD, a shift from their standard fare of food, drugs, and dietary supplements. A consultant indicated that FDA says they’re concerned about potential risks to the liver and male reproductive system, interactions with certain medications, and the impact of CBD on vulnerable populations as well as pregnant women. Given that CBD's been a game-changer for Covid patients and those wrestling with opioid addiction, I wonder if the "vulnerable populations" he’s referring to are pets. They seem to like CBD. ;)

And speaking of delays, the DEA turned a blind eye for four years, disregarding a judge's directive to withdraw the license of Morris & Dickson Co for their “cavalier disregard” of opioid abuse prevention rules. Between 2014 and 2018, they dispatched 12,000 unusually large opioid orders, and only reported three as suspicious. Paul Dickson Sr, their CEO, put the "dick" in Dickson when he stated in 2019 that their compliance program was “dang good” and he didn’t think a “single person has gotten hurt by (their) drugs." Interestingly enough, the AP ran a piece on this last week, and just two days later, Morris & Dickson lost their license, effectively shutting them down. That's the power of journalism! :)

In more DEA Drama, a former DEA agent dismissed for using CBD is now taking his former boss to court. A word of caution to DEA agents – if you want to keep your job, best steer clear of cannabis and CBD. As we reported regarding a prior DEA scandal, Colombian cocaine might be the safer bet. Zing!

Feel free to subscribe to our Cannabis or Investors International News Roundups.

Have a wonderful week!
Jessica